A Phase 3 interventional study of CSL312 and Placebo in Hereditary Angioedema, sponsored by CSL Behring. Completed at 28 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 6th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:
CSL Behring · Sites in United States, Austria, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2021.
This study's enrollment of 64 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 61 across the 8 interventional studies, 259 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: For subjects taking any prophylactic HAE therapy during the 3 months before Screening, ≥ 3 HAE attacks may be documented over 3 consecutive months before commencing the prophylactic therapy.
Exclusion Criteria:
Participants received a CSL312 loading dose of 400 mg as two 200 mg SC injections in Month 1 along with CSL312 of 200 mg subcutaneous (SC) injections, once monthly from Months 2 to 6.
Biological: CSL312
Participants received a CSL312 matched loading dose of placebo as two SC injections in Month 1 along with CSL312 matched placebo SC injections, once monthly from Months 2 to 6.
Drug: Placebo
Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
Also known as: Factor XIIa inhibitor monoclonal antibody, garadacimab
Buffer without active ingredient
Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: First injection up to 6 months
Percentage Change in the Time-normalized Number of HAE Attacks Per Month During the Treatment Period Compared to the Run-in Period
Percentage change in the time-normalized number of HAE attacks was calculated within a participant as: 100 \* \[1 - (time-normalized number of HAE attacks per month during treatment period / time-normalized number of HAE attacks per month during run-in period)\]. Time-normalized number of HAE attacks per month during treatment period was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: 6 months, first 3-months and second 3-months of treatment period
Time-Normalized Number of HAE Attacks Per Month Requiring On-Demand Treatment
Time-normalized number of HAE attacks per month requiring on-demand treatment was calculated per participant as: \[number of HAE attacks requiring on-demand treatment / length of participant in days\] \* 30.4375.
Time frame: 6 months, first 3-months and second 3-months of treatment period
Time-Normalized Number of Moderate or Severe HAE Attacks Per Month
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: 6 months, first 3-months and second 3-months of treatment period
Time-normalized Number of HAE Attacks Per Month in the First 3-months and Second 3-months of Treatment Period
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: First 3-months and second 3-months of treatment period
Relative Difference in Means in the Time-Normalized Number of HAE Attacks Per Month Between CSL312 to Placebo
Relative difference in means in the time-normalized number of HAE attacks per month CSL312 to Placebo was calculated as: 100 \* \[(mean time-normalized number of HAE attacks for CSL312 - mean time-normalized number of HAE attacks for placebo) / mean time-normalized number of HAE attacks for placebo\]. Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: 6 months, first 3-months and second 3-months of treatment period
Percentage of Participants With a Response to Subject's Global Assessment of Response to Therapy (SGART)
SGART is a self-assessment by the participant and measures the subject's overall treatment response to the investigational product using the following ratings: 0 (none: worse or no response at all, not acceptable), 1 (poor: very little response, not acceptable), 2 (fair: some response, acceptable but could be better), 3 (good: good response, acceptable), and 4 (excellent: excellent response, as good as can be imagined).
Time frame: Up to 6 months
Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AEs of Special Interest (AESI)
AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.
Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Number of Participants With CSL312-induced Anti-CSL312 Antibodies
Time frame: Up to 8 months
Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs)
Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.
Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Percentage of Participants With at Least One AE, SAE, and AESI
AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.
Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Percentage of Participants With CSL312-induced Anti-CSL312 Antibodies
Time frame: Up to 6 months
Percentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs
Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.
Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Participants were enrolled at study centers in Canada, Germany, Hungary, Israel, Japan, Netherlands, and the United States from 27 January 2021 to 07 June 2022.
| Milestone | CSL312 | Placebo |
|---|---|---|
| Started | 39 | 25 |
| Intention-to-treat (itt) analysis set | 39 | 25 |
| Safety analysis set | 39 | 25 |
| Completed | 38 | 22 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 |
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
| number of HAE attacks per month | CSL312 | Placebo |
|---|---|---|
| Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period | 0.27 ± 0.683 | 2.01 ± 1.341 |
Percentage change in the time-normalized number of HAE attacks was calculated within a participant as: 100 \* \[1 - (time-normalized number of HAE attacks per month during treatment period / time-normalized number of HAE attacks per month during run-in period)\]. Time-normalized number of HAE attacks per month during treatment period was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
| percentage change in HAE attacks/month | CSL312 | Placebo |
|---|---|---|
| 6 Months of Treatment | 90.67 ± 22.433 | 20.21 ± 42.661 |
| First 3-months of Treatment | 91.10 ± 21.255 | 18.89 ± 53.837 |
| Second 3-months of Treatment | 90.12 ± 25.624 | 29.87 ± 55.529 |
Time-normalized number of HAE attacks per month requiring on-demand treatment was calculated per participant as: \[number of HAE attacks requiring on-demand treatment / length of participant in days\] \* 30.4375.
| number of HAE attacks per month | CSL312 | Placebo |
|---|---|---|
| 6 Months of Treatment | 0.23 ± 0.663 | 1.86 ± 1.412 |
| First 3-months of Treatment | 0.24 ± 0.748 | 1.76 ± 1.378 |
| Second 3-months of Treatment | 0.23 ± 0.610 | 1.80 ± 1.626 |
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.
| number of HAE attacks per month | CSL312 | Placebo |
|---|---|---|
| 6 Months of Treatment | 0.13 ± 0.296 | 1.35 ± 1.166 |
| First 3-months of Treatment | 0.12 ± 0.305 | 1.25 ± 1.091 |
| Second 3-months of Treatment | 0.13 ± 0.320 | 1.24 ± 1.296 |
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
| number of HAE attacks per month | CSL312 | Placebo |
|---|---|---|
| First 3-months of Treatment | 0.26 ± 0.749 | 1.97 ± 1.287 |
| Second 3-months of Treatment | 0.28 ± 0.652 | 1.86 ± 1.603 |
Relative difference in means in the time-normalized number of HAE attacks per month CSL312 to Placebo was calculated as: 100 \* \[(mean time-normalized number of HAE attacks for CSL312 - mean time-normalized number of HAE attacks for placebo) / mean time-normalized number of HAE attacks for placebo\]. Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.
| number of HAE attacks per month | CSL312 and Placebo Comparison Group |
|---|---|
| 6 Months of Treatment | -86.51 (-95.68 to -57.84) |
| First 3-months of Treatment | -86.64 (-95.87 to -56.76) |
| Second 3-months of Treatment | -85.01 (-95.62 to -48.74) |
SGART is a self-assessment by the participant and measures the subject's overall treatment response to the investigational product using the following ratings: 0 (none: worse or no response at all, not acceptable), 1 (poor: very little response, not acceptable), 2 (fair: some response, acceptable but could be better), 3 (good: good response, acceptable), and 4 (excellent: excellent response, as good as can be imagined).
| percentage of participants | CSL312 | Placebo |
|---|---|---|
| None | 2.6 | 41.7 |
| Poor | 7.9 | 16.7 |
| Fair | 7.9 | 8.3 |
| Good | 15.8 | 20.8 |
| Excellent | 65.8 | 12.5 |
AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.
| Participants | CSL312 | Placebo |
|---|---|---|
| AE | 25 | 15 |
| SAE | 1 | 0 |
| AESI | 0 | 0 |
| Participants | CSL312 | Placebo |
|---|---|---|
| Number of Participants With CSL312-induced Anti-CSL312 Antibodies | 1 | 0 |
Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.
| Participants | CSL312 | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs) | 1 | 2 |
AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.
| percentage of participants | CSL312 | Placebo |
|---|---|---|
| AE | 64.1 | 60.0 |
| SAE | 2.6 | 0 |
| AESI | 0 | 0 |
| percentage of participants | CSL312 | Placebo |
|---|---|---|
| Percentage of Participants With CSL312-induced Anti-CSL312 Antibodies | 2.6 | 0 |
Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.
| percentage of participants | CSL312 | Placebo |
|---|---|---|
| Percentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs | 2.6 | 8.0 |
Collected over From first dose of study drug up to 3 months after the last injection (approximately 8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CSL312 | 0/39 (0%) | 1/39 (2.6%) | 17/39 (43.6%) |
| Placebo | 0/25 (0%) | 0/25 (0%) | 12/25 (48%) |
| Event | CSL312 | Placebo |
|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 1/39 | 0/25 |
| Event | CSL312 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/39 | 4/25 |
| COVID-19Infections and infestations | 0/39 | 3/25 |
| FatigueGeneral disorders | 0/39 | 3/25 |
| Upper respiratory tract infectionInfections and infestations | 4/39 | 2/25 |
| Injection site erythemaGeneral disorders | 1/39 | 2/25 |
| PyrexiaGeneral disorders | 1/39 | 2/25 |
| NauseaGastrointestinal disorders | 0/39 | 2/25 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/39 | 2/25 |
| NasopharyngitisInfections and infestations | 3/39 | 1/25 |
| Gastrointestinal infectionInfections and infestations | 2/39 | 1/25 |
ITT analysis set included all the randomized participants who provided written informed consent and underwent study screening procedures.
| Age, Continuous(years) | CSL312 | Placebo | Total |
|---|---|---|---|
| Mean | 43.3 ± 17.45 | 37.8 ± 12.80 | 41.2 ± 15.92 |
| Sex: Female, Male(Participants) | CSL312 | Placebo | Total |
|---|---|---|---|
| Female | 24 | 14 | 38 |
| Male | 15 | 11 | 26 |
| Ethnicity (NIH/OMB)(Participants) | CSL312 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 37 | 23 | 60 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | CSL312 | Placebo | Total |
|---|---|---|---|
| Race — Asian | 4 | 2 | 6 |
| Race — Black or African American | 0 | 1 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Race — White | 33 | 22 | 55 |
| Race — Other | 1 | 0 | 1 |
| Region of Enrollment(participants) | CSL312 | Placebo | Total |
|---|---|---|---|
| Canada | 5 | 3 | 8 |
| Netherlands | 2 | 1 | 3 |
| Hungary | 2 | 0 | 2 |
| United States | 12 | 9 | 21 |
| Japan | 4 | 2 | 6 |
| Israel | 7 | 2 | 9 |
| Germany | 7 | 8 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Ran from Jan 2021 to primary completion in Jun 2022, 16 months.
Results were first posted in Jun 2023, 1 year after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab